CVE-2017-17678 — MEDIUM (6.1)

Vulnerability Description

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

CVSS Score

6.1

MEDIUM

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Attack Vector

NETWORK

Attack Complexity

LOW

Privileges Required

NONE

User Interaction

REQUIRED

Scope

CHANGED

Confidentiality

LOW

Integrity

LOW

Availability

NONE

Affected Products

Vendor	Product	Versions
Bmc	Remedy Mid-Tier	9.1

Related Weaknesses (CWE)

CWE-79

References

http://bmc.comProduct
http://remedy.comProduct
https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-sRelease NotesVendor Advisory
https://seclists.org/fulldisclosure/2017/Oct/52Mailing ListThird Party Advisory
http://bmc.comProduct
http://remedy.comProduct
https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-sRelease NotesVendor Advisory
https://seclists.org/fulldisclosure/2017/Oct/52Mailing ListThird Party Advisory

FAQ

What is CVE-2017-17678?

CVE-2017-17678 is a vulnerability with a CVSS score of 6.1 (MEDIUM). BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

How severe is CVE-2017-17678?

CVE-2017-17678 has been rated MEDIUM with a CVSS base score of 6.1/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2017-17678?

Check the references section above for vendor advisories and patch information. Affected products include: Bmc Remedy Mid-Tier.